Exploratory Reta stack
BPC-157 preclinical literature alongside a separate metabolic-receptor record.
Community-referenced selection · combination unvalidated
No supporting controlled human study of this exact combination was identified in our September 5, 2026 review. Safety and efficacy together are unestablished. The BPC-157 source does not establish prevention or treatment of gastrointestinal side effects from the anchor compound. Preclinical findings do not validate this combination in people.
Collects metabolic-receptor literature and separate BPC-157 preclinical research without assigning a symptom-management role. Retatrutide is the only metabolic-receptor anchor in this collection. Each material remains a separate product record.
Published findings concern the stated study materials and models. They do not establish the exact catalog combination.
Individual product records, together for review.
1 vial
$120
PDL-RT3 is the catalog alias for a synthetic peptide analogue in the triple incretin-receptor research class. Its laboratory record identifies the underlying analyte separately, while the catalog material is supplied as a sealed vial of lyophilized powder for analytical research.
Lot documentation published
1 vial
$45
BPC-157 is a synthetic pentadecapeptide composed of 15 amino-acid residues. It belongs to the short synthetic peptide research category described in the catalog literature and is supplied as a sealed vial of lyophilized powder for laboratory research and analytical characterization.
Lot documentation published
One vial of each included product.
Individual value: $165Save $15
Ask about Reta + BPC-157
Contact us for current availability and lot documentation for the products in this selection.
Laboratory research only. Goal labels describe research themes, not promised outcomes or combined-use guidance. Each product is a separate catalog record. Not for human or veterinary use.